Author | Giuliana Grossi

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for children and adolescents with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

The risk of adverse outcomes increased the most in pregnancies with antirheumatic treatment, especially those treated with biologic disease modifying antirheumatic drugs (bDMARDs), when compared with controls.

Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.